Last reviewed · How we verify
NCT04289337
Double-blind Clinical Trials of Probiotic Products in Oral Health.
NA trial testing Combined probiotics (1) in Probiotics in 130 participants. Completed in 6 December 2019.
2 December 2019
Quick facts
| Lead sponsor | Glac Biotech Co., Ltd |
|---|---|
| Phase | NA |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | double |
| Primary purpose | prevention |
| Enrollment | 130 |
| Start date | 21 October 2019 |
| Primary completion | 2 December 2019 |
| Estimated completion | 6 December 2019 |
| Sites | 1 location across Taiwan |
Drugs / interventions tested
- Combined probiotics (1)
- Combined probiotics (2)
- Combined heat-killed probiotics (1)
- Combined heat-killed probiotics (2)
- Probiotic metabolites
- Placebo
Conditions studied
- Probiotics — all drugs for Probiotics →
- Oral Health — all drugs for Oral Health →
- Probiotic Metabolites — all drugs for Probiotic Metabolites →
Sponsor
Glac Biotech Co., Ltd
Who can join
Adults 20 to 40, any sex, with Probiotics or Oral Health. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
In order to evaluate the effects of supplementary probiotics and their metabolites on oral environment and oral microbiota, Taiwan FDA No. 88037803 will be used to evaluate the effects of oral probiotic candidate strains from previous research results and develop oral probiotic products.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT04289337
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Probiotics
Currently open trials in the same condition.
- NCT07182890 — Efficacy of Clostridium Butyricum in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia · Phase 4 · recruiting
- NCT07187492 — Efficacy of Bacillus Coagulans in Alleviating Anxiety and Depression in Patients With Functional Dyspepsia · Phase 4 · recruiting
- NCT07029360 — Effectiveness of Coenzyme Q10 and Probiotics in Periodontal Therapy During Pregnancy · NA · recruiting
- NCT06872320 — The Influence of Probiotics on Metabolome and Heart Rate Variability in Heart Failure of Structure Heart Disease · NA · active not recruiting
- NCT06904573 — Probiotics in Advanced Urothelial Carcinoma · Phase 2 · recruiting
Other Glac Biotech Co., Ltd trials
Trials by the same sponsor.
- NCT07530081 — The Impact of Oral Probiotics on Improving the Quality of Life in Patients With Dysmenorrhea. · NA · active not recruiting
- NCT07532837 — The Effect of Oral Probiotics on Allergic Rhinitis Symptoms and the Quality of Life · NA · active not recruiting
- NCT05286047 — Probiotic on Atopic Dermatitis in Infant · NA · completed
- NCT05492448 — Probiotic on Type 2 Diabetes and Chronic Obstruction Pulmonary Disease · NA · terminated
- NCT06092723 — Effects of Probiotics Improves the Endurance and Explosiveness Exercise Performance on Healthy Human. · NA · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04289337 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Glac Biotech Co., Ltd
- Last refreshed: 28 February 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04289337.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing